Publications by authors named "Marijke B Coomans"
Article Synopsis
- The study focuses on maintaining health-related quality of life (HRQoL) for glioma patients during their progression-free survival (PFS) period.
- Analysis of HRQoL data from past trials shows that 47% of patients experienced deterioration in HRQoL despite not progressing in the disease, with only poor performance status being a significant factor linked to this decline.
- The findings highlight the need for regular monitoring of patients' well-being throughout their treatment to identify and address HRQoL issues early on.
Article Synopsis
- Two methods for combining survival and health-related quality of life (HRQoL) data in glioma trials—Quality-adjusted effect sizes (QASES) and joint modeling (JM)—were evaluated for calculating "net clinical benefit."
- In the EORTC 26951 trial, additional treatments improved overall survival but negatively impacted HRQoL, leading to a notable decrease in perceived survival benefit when adjusting for symptoms like appetite loss and nausea.
- The findings indicate that while both methods provided different outcomes, accounting for HRQoL diminished the apparent benefits of survival from treatments in glioma trials.
Background: Different analytical methods may lead to different conclusions about the impact of treatment on health-related quality of life (HRQoL). This study aimed to examine 3 different methods to evaluate change in HRQoL and to study whether these methods result in different conclusions.
Methods: HRQoL data from 15 randomized clinical trials were combined (CODAGLIO project).
Background: Health-related quality of life (HRQoL) has become an increasingly important patient-reported outcome in glioma studies. Ideally, collected HRQoL data should be exploited to the full, with proper analytical methods. This systematic review aimed to provide an overview on how HRQoL data is currently evaluated in glioma studies, focusing on the research objectives and statistical analyses of HRQoL data.
View Article and Find Full Text PDFArticle Synopsis
- Symptom management in glioma patients is complex, with many experiencing multiple symptoms simultaneously; the study aimed to identify symptom clusters and their impact on functioning.
- Data from the CODAGLIO project, involving 4,307 glioma patients, revealed four major symptom clusters: motor, fatigue, pain, and gastrointestinal/seizures/bladder control.
- The motor and fatigue symptom clusters were significantly linked to reduced physical and role functioning in patients, underscoring the need for targeted symptom management strategies.
Purpose Of Review: Increased life expectancy in brain tumour patients had led to the need for strategies that preserve and improve cognitive functioning, as many patients suffer from cognitive deficits. The tumour itself, as well as antitumor treatment including surgery, radiotherapy and chemotherapy, supportive treatment and individual patient factors are associated with cognitive problems. Here, we review the recent literature on approaches that preserve and improve cognitive functioning, including pharmacological agents and rehabilitation programs.
View Article and Find Full Text PDFFatigue is the most prevalent and disabling symptom in cancer patients. Yet, scientific literature on this topic is scarce and reports disparate results. This study systematically reviews how fatigue is assessed in patients with low-grade glioma and evaluates its prevalence in LGG patients.
View Article and Find Full Text PDF